SecBot SecBot
8-K ·Filed Apr 30, 2026

SEM

SELECT MEDICAL HOLDINGS CORP
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001104659-26-053056
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The stock trades near the $16.50 take-private price, limiting upside. The operational weakness in the core critical illness segment (15.3% EBITDA decline) is concerning but likely overshadowed by the pending merger. Monitor for stockholder vote and regulatory approvals, any delay or termination risk would expose downside to fair value in the $12-14 range based on deteriorating fundamentals.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$16.38
T+0 close · Apr 30, 2026 · via day close
Latest settled
+0.81%
T+20 · $16.51
Vs SPY
−4.45%
α at T+20
Next horizon
T+60
due 4mo ago
  1. T+0 · May 1 $16.38entry
  2. T+1 · 7mo ago 0.00%α +0.34% · $16.38
  3. T+5 · 6mo ago −0.18%α −2.53% · $16.35
  4. T+20 · 6mo ago +0.81%α −4.45% · $16.51
  5. T+60 · due 4mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Select Medical reported Q1 2026 revenue of $1.42B (+5.0% YoY) but EPS of $0.35 declined 20.5% YoY, missing the $0.43 consensus. Operating income fell 12.7% and Adjusted EBITDA dropped 6.5% as the critical illness recovery hospital segment saw a 15.3% EBITDA decline. The company maintained its 2026 guidance and declared a $0.0625 dividend. Separately, the pending take-private merger at $16.50/share (no financing condition, HSR waiting period expired) continues to progress toward a mid-2026 close, which will likely cap the stock near the deal price.

Key Financial Metrics

EPS
$0.35
est $0.43 · -18.6%
Revenue
$1.4B
est $1.4B · +0.8% · +5.0% YoY
Rating
miss
Guidance
$5.6B-$5.8B
maintained

Key Facts

  • Q1 2026 revenue $1.421B (+5.0% YoY) vs $1.353B prior year
  • GAAP EPS $0.35 vs $0.44 YoY (-20.5%), missed consensus of $0.43
  • Operating income fell 12.7% to $98.4M from $112.7M
  • Adjusted EBITDA declined 6.5% to $141.6M from $151.4M
  • Critical illness recovery hospital EBITDA dropped 15.3% to $73.4M; margin compressed from 13.6% to 11.5%
  • Outpatient rehab EBITDA fell 9.4% to $22.0M; margin down from 7.9% to 6.8%
  • Rehab hospital segment was the bright spot: EBITDA +15.1% to $81.1M, margin 23.0%
  • 2026 guidance maintained: revenue $5.6B-$5.8B, Adj. EBITDA $520M-$540M, EPS $1.22-$1.32
  • Pending take-private merger at $16.50/share; HSR waiting period expired April 27, 2026; expected close mid-2026
  • Equity award vesting deferred for Chairman Ortenzio and EVP Jackson by one year
  • Quarterly dividend of $0.0625/share declared

Financial Impact

EPS miss of ~18.6% vs consensus ($0.35 actual vs $0.43 est); operating income decline of $14.3M YoY; Adj. EBITDA decline of $9.9M YoY

epsoperating incomeadjusted ebitdacritical illness recovery hospital margins

Risk Factors

  • Merger fails to close, stock would reprice to reflect declining earnings trajectory
  • Critical illness recovery hospital margins continue compressing (11.5% vs 13.6% last year)
  • Outpatient rehab segment margin erosion (6.8% vs 7.9%) may persist
  • Labor cost inflation pressuring cost of services (+6.3% vs revenue +5.0%)

Market Snapshot

Exchange
NYSE
Sector
Services-Hospitals
Analyst Consensus
44% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-053056
Document: tm2613082d1_8k.htm0001104659-26-053056
Document: 0001104659-26-053056-index-headers.html0001104659-26-053056
Document: 0001104659-26-053056-index.html0001104659-26-053056
Document: 0001104659-26-053056.txt0001104659-26-053056
8-K Data (Synthetic)0001104659-26-053056

Track record

8 reports on SEM

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Jul 13, 202618w ago 15-12G Neutral 4/10 No price data
  2. Jul 1, 202619w ago 25-NSE Neutral 9/10 Entry $16.52 No price data
  3. Jul 1, 202619w ago 8-K Bullish 8/10 Entry $16.52 No price data
  4. Jun 26, 202620w ago 8-K Bullish 7/10 Entry $16.53 No price data
  5. Apr 30, 202628w ago 8-K Bearish 6/10 Viewing Entry $16.38 to $16.51 ▼ −0.81% +4.45% vs SPY
  6. Apr 15, 202630w ago PREM14A Bullish 8/10 Entry $16.38 to $16.45 ▲ +0.43% −5.62% vs SPY
  7. Mar 4, 202636w ago DEFA14A Neutral 3/10 Entry $16.25 to $16.29 ▲ +0.25% +4.66% vs SPY
  8. Mar 3, 202636w ago DEFA14A Bullish 9/10 Entry $16.26 to $16.29 ▲ +0.18% +4.59% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026